Pesquisar
Palvella Therapeutics Inc
PVLAAdicionar à lista de desejos
114.240USD
-4.730-3.98%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
1.64BValor de mercado
PerdaP/L TTM
Mais detalhes de Palvella Therapeutics Inc Empresa
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Informações de Palvella Therapeutics Inc
Código da empresaPVLA
Nome da EmpresaPalvella Therapeutics Inc
Data de listagemDec 18, 2014
CEOKaupinen (Wesley H)
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 18
Endereço353 W. Lancaster Avenue
CidadeWAYNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19087
Telefone14842531461
Sitehttps://palvellatx.com/
Código da empresaPVLA
Data de listagemDec 18, 2014
CEOKaupinen (Wesley H)
Executivos da empresa Palvella Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
477.21K
--
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
201.13K
--
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
53.69K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey (Jeff) Martini, Ph.D.
Dr. Jeffrey (Jeff) Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
477.21K
--
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
201.13K
--
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
53.69K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
6.22%
BVF Partners L.P.
6.13%
Kaupinen (Wesley H.)
5.76%
Frazier Life Sciences Management, L.P.
5.04%
First Light Asset Management, LLC
4.94%
Outro
71.91%
Investidores
Investidores
Proporção
Suvretta Capital Management, LLC
6.22%
BVF Partners L.P.
6.13%
Kaupinen (Wesley H.)
5.76%
Frazier Life Sciences Management, L.P.
5.04%
First Light Asset Management, LLC
4.94%
Outro
71.91%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
25.54%
Investment Advisor
23.56%
Hedge Fund
20.39%
Individual Investor
11.65%
Private Equity
6.89%
Research Firm
1.60%
Sovereign Wealth Fund
0.84%
Venture Capital
0.83%
Bank and Trust
0.45%
Outro
8.25%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
267
11.89M
82.90%
+1.54M
2025Q4
203
9.67M
81.68%
+2.49M
2025Q3
145
6.92M
62.61%
+1.10M
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Suvretta Capital Management, LLC
892.40K
7.03%
+70.00K
+8.51%
Dec 31, 2025
BVF Partners L.P.
879.01K
6.93%
-282.24K
-24.30%
Dec 31, 2025
Kaupinen (Wesley H.)
1.61M
12.67%
--
--
Apr 14, 2025
Frazier Life Sciences Management, L.P.
722.40K
5.69%
--
--
Dec 31, 2025
First Light Asset Management, LLC
709.14K
5.59%
+167.60K
+30.95%
Dec 31, 2025
Jennison Associates LLC
387.48K
3.05%
+280.57K
+262.44%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
507.39K
4%
+57.99K
+12.91%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
368.04K
2.9%
+28.99K
+8.55%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
ALPS Medical Breakthroughs ETF
0.37%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
iShares Russell 2000 Growth ETF
0.03%
Global X Russell 2000 ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Ver Mais
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.51%
ALPS Medical Breakthroughs ETF
Proporção0.37%
iShares Micro-Cap ETF
Proporção0.11%
Vanguard US Momentum Factor ETF
Proporção0.1%
iShares Russell 2000 Growth ETF
Proporção0.03%
Global X Russell 2000 ETF
Proporção0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0.02%
ProShares Hedge Replication ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
